Erbulozole
![]() | |
| Clinical data | |
|---|---|
| Other names | Erbuzole |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H27N3O5S |
| Molar mass | 469.56 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Erbulozole (R55104) is a congener of the microtubule inhibitor tubulozole. It is undergoing phase I clinical trials as a chemotherapeutic agent.[1]
Synthesis

References
Other reading
- Distelmans W, VanGinckel P, Heeres J, Van der Veken LJ (1991). "Erbulozole. Antineoplastic, Microtubule inhibitor". Drugs Future. 16 (6): 577.
| CI monoclonal antibodies ("-mab") |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine kinase inhibitors ("-nib") |
| ||||||||
| Other |
| ||||||||
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.
